SFI
YMAB

Susquehanna Fundamental Investments’s Y-mAbs Therapeutics YMAB Stock Holding History

Susquehanna Fundamental Investments’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26,482
Closed -$181K – 700
2023
Q4 		$181K Sell
26,482
-14,478
-35% -$83.7K 0.18% 57
2023
Q3 		$223K Hold
40,960
– – 0.01% 323
2023
Q2 		$278K Hold
40,960
– – 0.01% 530
2023
Q1 		$205K Sell
40,960
-1,718
-4% -$7.01K ﹤0.01% 860
2022
Q4 		$208K Buy
+42,678
New +$310K ﹤0.01% 1064

Other funds holding YMAB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Fundamental Investments's YMAB Position: Q1 2024 in Review

Susquehanna Fundamental Investments sold out of Y-mAbs Therapeutics (YMAB) in Q1 2024, closing a stake of 26,482 shares — an estimated $181K sold.

Susquehanna Fundamental Investments first reported a position in YMAB in Q4 2022 and held it in 5 quarters. The position peaked at $278K in Q2 2023. 96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

  • Susquehanna Fundamental Investments reported no remaining Y-mAbs Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 26,482 Y-mAbs Therapeutics shares in Q1 2024, an estimated $181K.
  • Susquehanna Fundamental Investments first reported a position in Y-mAbs Therapeutics in Q4 2022 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's Y-mAbs Therapeutics position peaked at $278K in Q2 2023.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2024, filed 7 May 2024.